FDA OncoCure-TRKi coverage for business development, investment, and market access teams
OncoCure has achieved FDA approval for its innovative TRK inhibitor, offering new hope for patients with NTRK tumors and advancing targeted cancer treatment.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
